Literature DB >> 21514129

Dengue vaccines: progress and challenges.

Beth-Ann G Coller1, David E Clements.   

Abstract

With several dengue vaccine candidates progressing through clinical trials, several options for controlling this disease appear feasible. This would represent a major achievement and reflect decades of research and development activities. The challenges associated with the limited understanding of protective responses and those factors which determine disease severity remain, but with prospective studies ongoing in various dengue endemic areas and the initiation of dengue vaccine efficacy trials, immune responses are being evaluated in the context of protection and severe disease and these studies are highly likely to provide additional insights.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21514129     DOI: 10.1016/j.coi.2011.03.005

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  38 in total

1.  An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target.

Authors:  Matthew K Howe; Brittany L Speer; Philip F Hughes; David R Loiselle; Subhash Vasudevan; Timothy A J Haystead
Journal:  Antiviral Res       Date:  2016-04-04       Impact factor: 5.970

2.  Low sensitivity of NS1 protein tests evidenced during a dengue type 2 virus outbreak in Santos, Brazil, in 2010.

Authors:  Alvina Clara Felix; Camila Malta Romano; Cristiane de Campos Centrone; Célia Lima Rodrigues; Lucy Villas-Boas; Evaldo Stanislau Araújo; Andréia Manso de Matos; Karina Inácio Carvalho; Celina Maria Turchi Martelli; Esper Georges Kallas; Claúdio Sérgio Pannuti; José Eduardo Levi
Journal:  Clin Vaccine Immunol       Date:  2012-10-24

3.  Determinants of mortality from severe dengue in Brazil: a population-based case-control study.

Authors:  Giselle Hentzy Moraes; Eliane de Fátima Duarte; Elisabeth Carmen Duarte
Journal:  Am J Trop Med Hyg       Date:  2013-02-11       Impact factor: 2.345

4.  Vaccines today, vaccines tomorrow: a perspective.

Authors:  Christian Loucq
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15

5.  Correlation between serum levels of anti-endothelial cell autoantigen and anti-dengue virus nonstructural protein 1 antibodies in dengue patients.

Authors:  Hsien-Jen Cheng; Yueh-Hsia Luo; Shu-Wen Wan; Chiou-Feng Lin; Shan-Tair Wang; Nguyen Thanh Hung; Ching-Chuan Liu; Tzong-Shiann Ho; Hsiao-Sheng Liu; Trai-Ming Yeh; Yee-Shin Lin
Journal:  Am J Trop Med Hyg       Date:  2015-03-09       Impact factor: 2.345

6.  High-resolution crystal structure of FKBP12 from Aedes aegypti.

Authors:  Sreekanth Rajan; Kai Qian Saw; Quoc Toan Nguyen; Kwanghee Baek; Ho Sup Yoon
Journal:  Protein Sci       Date:  2012-05-18       Impact factor: 6.725

7.  Determination of viremia and concentration of circulating nonstructural protein 1 in patients infected with dengue virus in Mexico.

Authors:  Sergio I de la Cruz-Hernández; Hilario Flores-Aguilar; Silvia González-Mateos; Irma López-Martinez; Celia Alpuche-Aranda; Juan E Ludert; Rosa M del Angel
Journal:  Am J Trop Med Hyg       Date:  2013-01-21       Impact factor: 2.345

8.  Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.

Authors:  Janet C Lindow; Anna P Durbin; Stephen S Whitehead; Kristen K Pierce; Marya P Carmolli; Beth D Kirkpatrick
Journal:  Vaccine       Date:  2013-06-02       Impact factor: 3.641

9.  Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4.

Authors:  Gregory D Gromowski; Cai-Yen Firestone; Christopher T Hanson; Stephen S Whitehead
Journal:  Vaccine       Date:  2014-03-31       Impact factor: 3.641

10.  Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.

Authors:  Niyati Khetarpal; Rahul Shukla; Ravi Kant Rajpoot; Ankur Poddar; Meena Pal; Sathyamangalam Swaminathan; Upasana Arora; Navin Khanna
Journal:  Am J Trop Med Hyg       Date:  2016-11-07       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.